WO2001076617A3 - Oral tolerance induction by collagen to prevent allograft rejection - Google Patents

Oral tolerance induction by collagen to prevent allograft rejection Download PDF

Info

Publication number
WO2001076617A3
WO2001076617A3 PCT/US2001/008680 US0108680W WO0176617A3 WO 2001076617 A3 WO2001076617 A3 WO 2001076617A3 US 0108680 W US0108680 W US 0108680W WO 0176617 A3 WO0176617 A3 WO 0176617A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
allograft rejection
oral tolerance
tolerance induction
prevent allograft
Prior art date
Application number
PCT/US2001/008680
Other languages
French (fr)
Other versions
WO2001076617A2 (en
Inventor
David S Wilkes
Original Assignee
David S Wilkes
Advanced Res & Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David S Wilkes, Advanced Res & Tech Inst filed Critical David S Wilkes
Priority to AU2001245848A priority Critical patent/AU2001245848A1/en
Priority to CA2402489A priority patent/CA2402489C/en
Publication of WO2001076617A2 publication Critical patent/WO2001076617A2/en
Publication of WO2001076617A3 publication Critical patent/WO2001076617A3/en
Priority to US10/243,797 priority patent/US7348005B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of collagen and MHC-like compounds to down regulate immune responses. Methods for administration of such compounds that induce immune tolerance are described. The invention is important in the context of allograft rejection, transplantation, graft rejection, pleural disease and immunotolerance.
PCT/US2001/008680 2000-03-15 2001-03-15 Oral tolerance induction by collagen to prevent allograft rejection WO2001076617A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001245848A AU2001245848A1 (en) 2000-03-15 2001-03-15 Oral tolerance induction by collagen to prevent allograft rejection
CA2402489A CA2402489C (en) 2000-03-15 2001-03-15 Oral tolerance induction by collagen to prevent allograft rejection
US10/243,797 US7348005B2 (en) 2000-03-15 2002-09-13 Oral tolerance induction by collagen to prevent allograft rejection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18942000P 2000-03-15 2000-03-15
US60/189,420 2000-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/243,797 Continuation US7348005B2 (en) 2000-03-15 2002-09-13 Oral tolerance induction by collagen to prevent allograft rejection

Publications (2)

Publication Number Publication Date
WO2001076617A2 WO2001076617A2 (en) 2001-10-18
WO2001076617A3 true WO2001076617A3 (en) 2002-04-25

Family

ID=22697251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008680 WO2001076617A2 (en) 2000-03-15 2001-03-15 Oral tolerance induction by collagen to prevent allograft rejection

Country Status (3)

Country Link
AU (1) AU2001245848A1 (en)
CA (1) CA2402489C (en)
WO (1) WO2001076617A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021058A1 (en) * 2002-05-17 2003-11-17 Chiesi Farma Spa MIXTURES OF SYNTHETIC LIPIDS OPTIMIZED FOR THE PREPARATION OF A RECONSTITUTED SURFACTANT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593698A (en) * 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593698A (en) * 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 October 1998 (1998-10-15), JOSIEN REGIS ET AL: "Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance.", XP002151204, Database accession no. PREV199800511546 *
DEMEESTER STEVEN R ET AL: "The bimodal expression of tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection.", JOURNAL OF IMMUNOLOGY, vol. 150, no. 6, 1993, pages 2494 - 2505, XP002180879, ISSN: 0022-1767 *
FELTS C ET AL: "Immunologic tolerance to collagen and glycosaminoglycan components of scleral allografts in humans. Evidence for T cell suppression.", JOURNAL OF PERIODONTOLOGY, (1981 OCT) 52 (10) 603-8., XP001030770 *
MARES DAVID C ET AL: "Type V collagen modulates alloantigen-induced pathology and immunology in the lung.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 23, no. 1, July 2000 (2000-07-01), pages 62 - 70, XP002180880, ISSN: 1044-1549 *
TRANSPLANTATION (BALTIMORE), vol. 66, no. 7, 15 October 1998 (1998-10-15), pages 887 - 893, ISSN: 0041-1337 *

Also Published As

Publication number Publication date
CA2402489A1 (en) 2001-10-18
AU2001245848A1 (en) 2001-10-23
CA2402489C (en) 2011-11-01
WO2001076617A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
EP2281568A3 (en) Uses of soluble CTLA4 mutant molecules
IL245955A0 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CA2469369A1 (en) Compositions containing both sedative and non-sedative antihistamines
WO2002080965A3 (en) Vaccine composition
AU2002307791A1 (en) Composite scaffolds and methods using same for generating complex tissue grafts
WO2004094596A8 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
EG23321A (en) Artificial dermis and method of preparation.
WO2001057082A3 (en) Extraction of growth factors from tissue
WO2001077299A3 (en) A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
WO2004091572A3 (en) Cochleate compositions directed against expression of proteins
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
EP1173204A4 (en) Mutant human cd80 and compositions for and methods of making and using the same
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
NO20041212L (en) Autologous growth factor cocktail composition, method of preparation and use thereof.
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
WO2001076617A3 (en) Oral tolerance induction by collagen to prevent allograft rejection
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
AU2002219485A1 (en) An autologous anti-cancer vaccine
AU2002353078A1 (en) Tissue graft compositions and methods for producing same
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases
WO2002081521A3 (en) Osteoprotegerin in milk
IL153576A0 (en) Dna vaccines encoding hiv accessory proteins
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2402489

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10243797

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP